全文获取类型
收费全文 | 1507篇 |
免费 | 131篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 36篇 |
妇产科学 | 6篇 |
基础医学 | 124篇 |
口腔科学 | 21篇 |
临床医学 | 176篇 |
内科学 | 240篇 |
皮肤病学 | 6篇 |
神经病学 | 104篇 |
特种医学 | 202篇 |
外科学 | 171篇 |
综合类 | 57篇 |
预防医学 | 207篇 |
眼科学 | 18篇 |
药学 | 120篇 |
肿瘤学 | 164篇 |
出版年
2022年 | 11篇 |
2021年 | 21篇 |
2020年 | 17篇 |
2019年 | 31篇 |
2018年 | 22篇 |
2017年 | 17篇 |
2016年 | 14篇 |
2015年 | 19篇 |
2014年 | 27篇 |
2013年 | 40篇 |
2012年 | 51篇 |
2011年 | 64篇 |
2010年 | 54篇 |
2009年 | 49篇 |
2008年 | 42篇 |
2007年 | 74篇 |
2006年 | 47篇 |
2005年 | 78篇 |
2004年 | 46篇 |
2003年 | 53篇 |
2002年 | 40篇 |
2001年 | 60篇 |
2000年 | 53篇 |
1999年 | 39篇 |
1998年 | 53篇 |
1997年 | 56篇 |
1996年 | 40篇 |
1995年 | 33篇 |
1994年 | 22篇 |
1993年 | 20篇 |
1992年 | 17篇 |
1991年 | 20篇 |
1990年 | 28篇 |
1989年 | 27篇 |
1988年 | 37篇 |
1987年 | 27篇 |
1986年 | 29篇 |
1985年 | 30篇 |
1984年 | 16篇 |
1983年 | 17篇 |
1982年 | 24篇 |
1981年 | 11篇 |
1980年 | 21篇 |
1979年 | 10篇 |
1978年 | 16篇 |
1977年 | 16篇 |
1976年 | 24篇 |
1975年 | 9篇 |
1969年 | 10篇 |
1968年 | 11篇 |
排序方式: 共有1660条查询结果,搜索用时 15 毫秒
1.
Sean J. Barnett M.S. M.D. Christopher Stanley B.S. Melanie Hanlon R.N. C.N.P. Robert Acton M.D. Daniel A. Saltzman M.D. Ph.D. Sayeed Ikramuddin M.D. Henry Buchwald M.D. Ph.D. 《Surgery for obesity and related diseases》2005,1(4):1609-398
PURPOSE: Obesity has become a health-care crisis in the United States. Adolescent obesity is now one of the most common childhood disorders, with 4.7 million American adolescents having a body mass index (BMI) greater than the 95th percentile. Most patients do not respond to diet modification or exercise programs and attention is now turning toward surgery as a source of weight loss in adolescents. Few studies have looked at the overall morbidity and mortality of weight loss surgery in this patient population. METHODS: This is a retrospective study of medical charts of 15 bariatric surgical procedures performed on 14 adolescents without known genetic syndromes associated with severe childhood obesity from 1971 to 2001 at the University of Minnesota. Procedures performed on these patients included vertical banded gastroplasty (n = 7), Roux-en-Y gastric bypass (n = 5), and jejunoileal bypass (n = 3). Jejunoileal bypass procedures were performed from 1971 to 1977, after which time this procedure was abandoned. Patient age ranged from 13 to 17 years (mean, 15.7 years). Mean follow-up time was 6 years, with 9 patients available for long-term follow-up. RESULTS: All procedures were performed using an open technique by 1 surgeon. There were no perioperative deaths; complications included 1 case of wound infection, 2 episodes of dumping syndrome that resolved without revision, 1 episode of hypoglycemia, and 1 case of short-term electrolyte imbalance in a patient who underwent jejunoileal bypass. The average BMI dropped from 58.5 +/- 13.7 to 32.1 +/- 9.7 kg/m(2) (P < .01)--a 45% reduction. CONCLUSIONS: Surgery for morbid obesity is safe and results in significant weight loss in adolescents who fail medical therapy. 相似文献
2.
D P Hanlon 《The Journal of emergency medicine》1992,10(5):559-560
Bilateral Achilles tendon rupture is an unusual injury. This rare entity usually occurs in patients on chronic steroid therapy or with underlying disease. Bilateral Achilles tendon rupture is extremely rare in a previously healthy individual. A case involving traumatic Achilles tendon rupture as a result of a sky diving accident is reported. Evaluation of patients with suspected Achilles tendon rupture is briefly reviewed. 相似文献
3.
Golli M; Van Nhieu JT; Mathieu D; Zafrani ES; Cherqui D; Dhumeaux D; Vasile N; Rahmouni A 《Radiology》1994,190(3):741
4.
Five members in three generations of a family were affected by an illness that had many clinical features of the hypokalemic form of periodic paralysis (HPP). The serum potassium was either moderately reduced or normal during attacks, and there was no evidence of myotonia or cold-intolerance. All of the patients improved to a variable degree with oral potassium supplements, and 3 responded favorably to triamterene. The usually beneficial drug acetazolamide, however, invariably caused weakness in these patients, an effect previously described in only one other family with HPP. In addition, amphetamine-like sympathomimetic drugs effectively aborted or prevented paralysis in several members. Muscle biopsy in two patients revealed some unusual features, and electromyography showed myopathic potentials. There was no evidence of diabetes. The urine electrolyte concentrations during glucose tolerance tests, however, were different from those previously reported in HPP. This family may represent a variant form of HPP. 相似文献
5.
6.
7.
8.
9.
MGC Hendriks P Dogterom JT Ebels B Oosterhuis LR Geertsema T Hulot G Bianchetti and JHG Jonkman 《Fundamental & clinical pharmacology》1998,12(5):559-565
Summary— In the present study we have compared the steady state biopharmaceutic characteristics of four diltiazem once daily controlled release capsules: Mono-Tildiem LP 300® (300 mg), Adizem® XL (300 mg)1, Cardizem® (300 mg) and Dilacor® (240 mg). Sixteen healthy male volunteers (aged 22.9 ± 3.3 years, range 19–31 years) completed an open label, multiple oral dose, randomized, four-period crossover study without a washout period in between. The volunteers received each diltiazem formulation once daily for four days. Trough diltiazem and metabolites plasma concentrations were determined on days 3 and 4. The 24-h plasma concentration-time profiles were assessed after the dose on day 4 of each period. The following steady state pharmacokinetic parameters for diltiazem were calculated: the minimum plasma concentration (cmin), the maximum plasma concentration (cmax), the time to reach that concentration (tmax), the time interval during which the plasma concentration exceeds 50% of cmax (t50), the area under the plasma concentration-time curve (AUC72–96) and the peak-to-trough fluctuation (PTF). For the metabolites of diltiazem, N-mono-desmethyl-diltiazem (NDM) and desacetyldiltiazem (DAD), AUC72–96 (AUCNDM and AUCDAD) and the ratio metabolite/parent compound were calculated. Steady state was achieved on day 3. Except one, all controlled release formulations have satisfactory controlled release properties allowing once daily administration. However, significant (P < 0.05) differences were found between the pharmacokinetic characteristics which do not allow exchange of the various formulations. Concentrations well below 50 ng·mL-1 in the morning hours were observed for Dilacor® (240 mg) and Adizem® XL (300 mg), which could be a disadvantage of these formulations as it is well-known that ischaemic events occur at a higher rate during that part of the day. The plasma concentration profiles of NDM and DAD, the major circulating metabolites, parallel the plasma concentration profiles for the parent compound. From a clinical point of view, all treatments were well tolerated. 相似文献
10.